Re: Zenith AGM webcast 9/12/2018

...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Reply New Message

Prev Message Back To Forum Threaded View Next Message

BearDownAZ

Rank: President [?]

Points: 25003 [?]

Votes: 68 Score: 4.5 [?]

Your Vote:

Please Log In to Vote

Did you know? You can earn activity points by filling your profile with information about yourself (what city you live in, your favorite team, blogs etc.)

Re: Zenith AGM webcast 9/12/2018

in response to

Re: Zenith AGM webcast 9/12/2018

bfw

posted on Sep 12, 2018 05:04PM

Thanks bfw. I wasn't expecting this until later tonight. I agree, there doesn't appear to be much new in the Zenith AGM slide deck other than updated treatment duration data in slide 16 (updated 8/22/18) for the combo mCRPC trial. Based on the frequent dose modifications of patient #6, I am guessing that patient #6 was the n=1 patient used in the CURATE.AI study. I will wait to comment any more on slide 16 until I hear the webcast narration.